This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TC-6499-12
Description: TC-6499 is a small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNR) as an agonist.
Targacept and GlaxoSmithKline
In July 2007, GlaxoSmithKline and Targacept announced a strategic alliance to discover, develop and market novel therapeutics that selectively target specified NNRs. TC-6499 is subject to a contingent future option of GlaxoSmithKline for an exclusive license under the terms of the parties' agreement. If licensed, Targacept retains an option to co-promote TC-6499 for pain to specialists and hospital-based physicians in the United States.
Targacept and Catalyst
In March 2015, Targacept and Catalyst Biosciences jointly announced that they have entered into a definitive agreement to merge the two companies. The combined entity will be named Catalyst Biosciences.
In March 2015, Targacept and Catalyst entered into an amendment to the definitive agreement to merge the two companies.
Pink Sheet GSK and Targacept partners in pain
Additional information available to subscribers only: